Early development of histiocytic sarcomas in p53 knockout mice treated with N-bis(2-hydroxypropyl)nitrosamine

AKIHIRO HIRATA¹², TETSUYA TSUKAMOTO¹, MASAMI YAMAMOTO¹, SHINJI TAKASU¹³, HIROKI SAKA¹³, HISAYO BAN¹, TOKUMA YANAI³, TOSHIAKI MASEGI³, LAWRENCE A. DONEhower⁴ and MASAE TATEMATSU¹

¹Division of Oncological Pathology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681; ²Division of Animal Experimentation, Life Science Research Center, Gifu University, 1-1 Yanagido, Gifu 501-1194; ³Department of Veterinary Pathology, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan; ⁴Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA

Received April 12, 2007; Accepted June 28, 2007

Abstract. p53 knockout mice have been utilized for the functional analysis of p53 in carcinogenic processes and for the evaluation of the carcinogenic potential of chemicals. In this study, we established that p53 knockout mice have an elevated susceptibility to the induction of histiocytic sarcoma (HS) by N-bis(2-hydroxypropyl)nitrosamine (BHP). p53 heterozygous (+/-) and wild-type (+/+) mice were treated with 20 or 200 ppm BHP in their drinking water for 15 weeks or with 20 ppm BHP for 40 weeks. An additional group of p53 nullizygous (-/-) mice were treated with 20 ppm BHP for 15 weeks. In a 15-week experiment, hepatic HSs were unexpectedly observed in BHP-treated p53 (-/-) mice (30.8%) but not in p53 (+/-) and (+/+) mice and untreated (-/-) mice, indicating that a complete loss of p53 dramatically accelerates the genesis of HS. In a 40-week experiment, HSs were significantly increased in female p53 (+/-) mice (37.5%) as compared with female (+/+) mice (5.0%). Additionally, PCR-SSCP and sequencing analysis revealed a high frequency of p53 gene mutations in HSs, demonstrating the involvement of p53 gene mutations in HS development. Our data add to the understanding of the carcinogenic susceptibility of p53 knockout mice, and may help to elucidate the pathogenesis of HS development.

Introduction

The tumor suppressor p53 plays a critical role in preventing the accumulation of the multiple genetic changes involved in tumor development (1). p53 knockout mice, first established by Donehower et al (2), have been utilized for the functional analysis of p53 in carcinogenic processes and, additionally, for the evaluation of the carcinogenic potential of chemicals (3). Histiocytic sarcoma (HS) is classified as a non-lymphoid hematopoietic neoplasm (4) and is thought, based on its immunohistochemical and ultrastructural features, to be derived from cells of mononuclear phagocyte lineage (5,6). It is a rare, spontaneous tumor in mice; at 24 months of age, incidences of it in common strains are between 0 and 5.5% (4,7). However, more frequent development has been reported in genetically engineered mice (8-12). It is noteworthy that this is also the case in animals with p53-related alterations. For example, it was reported that HS is the most common spontaneous tumor in p21-deficient mice, accounting for approximately half of all the lesions which develop (8). Loss of BAX alters the tumor spectrum in ARF-deficient mice and results in the emergence of HS (10). Using double-mutant mice, it was also demonstrated that coincident loss of ARF, a regulator of the p53 pathway, with INK4A and PTEN induced the development of HS (12). However, the relevance of p53 itself to HS development has remained unclear. Spontaneous development of HS has not been reported in p53 knockout mice, either in nullizygotes [p53 (-/-)] or heterozygous [p53 (+/-)], though they show markedly enhanced genesis of tumors of various types (2,13-18). The mechanisms underlying HS development are poorly understood, so it would appear that studies using genetically engineered mice are warranted.

N-bis(2-hydroxypropyl)nitrosamine (BHP) is a multi-organ genotoxic carcinogen in rodents, whose oral administration induces both lung and hepatic vascular tumors in mice (19). We previously reported on the carcinogenicity of BHP in p53 knockout mice, with a particular focus on differences in susceptibility with reference to lung and hepatic vascular tumors (20). BHP also rapidly induced HS in the livers of p53 nullizygous (-/-) and heterozygous (+/-) mice, though it was not expected that histiocytes would be the targets of this carcinogen. We therefore further investigated, in this study, HS development in BHP-treated p53 knockout mice, with a focus on the molecular mechanisms linked to p53 gene alteration.
Materials and methods

Animals. p53 knockout mice produced by Donehower et al (2) were backcrossed to C57BL/6J (N4) and maintained at the Animal Facility of Aichi Cancer Center Research Institute. Five-week-old males and females were used in the present experiment. They were housed at a maximum of 5 per plastic cage on wood chips in an air-conditioned room with a 12-h light-dark cycle, and given a basal diet (Oriental NMF, Oriental Yeast, Tokyo, Japan) and drinking water ad libitum.

Genotyping of each mouse was performed by PCR using 2 sets of primers (Table I), basically as previously described (21).

Experimental design. The experimental design is shown in Fig. 1. BHP (Nacalai Tesque, Kyoto, Japan) was dissolved in distilled water and freshly prepared two times per week. In experiment I, male and female p53 (+/+) and (+/-) mice were given drinking water ad libitum containing 20 or 200 ppm BHP in light-shielded bottles for 15 weeks. An additional group of p53 (-/-) male mice were treated with only 20 ppm BHP in light-shielded bottles for 15 weeks. In experiment II, long-term observation was performed using male and female p53 (+/+) and (+/-) mice of both sexes. BHP at 20 (gray bar) or 200 (closed bar) ppm and water (open bar) as a control were given. Exp., experiment; BHP, N-bis(2-hydroxypropyl)nitrosamine; S, sacrifice.

Histopathological analysis. Tissues were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer and were routinely processed to sections stained with hematoxylin and eosin (H&E). For the differential diagnosis of HS and lymphoma, the following immunohistochemical markers were used: rabbit anti-human CD3 polyclonal antibody (Dako Japan, Kyoto, Japan) for T-lymphocyte; rat anti-mouse CD45R/B220 monoclonal antibody (Pharmingen, San Diego, CA) for B-lymphocyte; and rat anti-mouse F4/80 monoclonal antibody (Serotec, Oxford, UK) for monocyte/macrophage detection. A standard avidin-biotin technique (Vectastain ABC kit, Vector Laboratories, Burlingame, CA) was employed with diaminobenzidine as the chromogen. Sections were counterstained with Meyer's hematoxylin to aid orientation.

Analysis of p53 gene alterations. Twelve hepatic HSs from BHP-treated p53 knockout mice, 2 from p53 (+/+), and 10 from (+/-) mice, were subjected to analysis of p53 gene alterations. In order to detect the loss of heterozygosity (LOH) of the p53 gene in the lesions of p53 (+/-) mice, PCR was

<table>
<thead>
<tr>
<th>Target</th>
<th>Primer sequence</th>
<th>Product length (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>5'-GTGTTTCATTAGTTCCCCACCTTGAC-3'</td>
<td>320</td>
</tr>
<tr>
<td></td>
<td>5'-ATGGGAGGCTGCCCCAGTCTAACC-3'</td>
<td></td>
</tr>
<tr>
<td>Mutant</td>
<td>5'-GTGGGAAGGAACAAAGTTGCAGGCCC-3'</td>
<td>150</td>
</tr>
<tr>
<td></td>
<td>5'-TTTACGAGCCCTGCGCTGATGT-3'</td>
<td></td>
</tr>
<tr>
<td>PCR-SSCP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exon 5 Sense</td>
<td>5'-TCTCTTCAGTACTCTCCTC-3'</td>
<td>214</td>
</tr>
<tr>
<td></td>
<td>5'-AGGCGGTGTTGGAGGCTTA-3'</td>
<td></td>
</tr>
<tr>
<td>Exon 6 Sense</td>
<td>5'-GGCTTCTGACCTTATCTGAC-3'</td>
<td>181</td>
</tr>
<tr>
<td></td>
<td>5'-CAACTGTCCTGAAAGCCAC-3'</td>
<td></td>
</tr>
<tr>
<td>Exon 7 Sense</td>
<td>5'-TCACCTGAGCTCTGTTGCTT-3'</td>
<td>170</td>
</tr>
<tr>
<td></td>
<td>5'-CAGGCTAACCCTACCTAC-3'</td>
<td></td>
</tr>
<tr>
<td>Exon 8 Sense</td>
<td>5'-ACTGCGCTTGTCAGTCCT-3'</td>
<td>279</td>
</tr>
<tr>
<td></td>
<td>5'-GGAGAGGCGCTTGTGACGG-3'</td>
<td></td>
</tr>
</tbody>
</table>

Table I. PCR primers for genotyping and for SSCP analysis of mouse p53.
performed to specifically amplify the wild or mutant allele with PCR primers for the genotyping of mice (Table I). PCR-single strand conformation polymorphism (SSCP) analysis was conducted basically as previously described (21). The four pairs of primers applied for mouse p53 exons 5-8 are listed in Table I. The primers for exon 5 were designed to specifically amplify the wild-type allele. Abnormal bands, separated by electrophoresis, were excised from the gels and subjected to sequencing analysis utilizing an ABI PRISM 3100 with a BigDye Terminator v3.1 Cycle Sequencing Ready Kit (Applied Biosystems, Forester City, CA). For tumor samples with p53 mutations at exons 7 and 8 in p53 (+/-) mice, long PCR was performed to selectively amplify the wild-type allele of the p53 gene using a Takara LA-PCR kit (Takara Bio, Shiga, Japan) as previously described (22). Due to the localization of mutations, a PCR sense primer for exon 5 was used in combination with antisense primers for exons 7 or 8 (Table I).

Statistical analysis. Data for incidences of tumors were analyzed using Fisher’s exact test. The survival of each genotype of mice was analyzed with the log-rank test.

Results

Mortality of mice of each genotype. In Experiment I, 3 untreated and 15 BHP-treated p53 (-/-) mice died before week...
Clusters of positively stained tumor cells were found (Fig. 2C), surface marker F4/80, were used to determine tumor origin. Immunohistochemical analyses, using the murine macrophage spontaneous tumor in p53 knockout mice (2,13,14,17). In the differential diagnosis as lymphoma is the most frequent from lymphomas (24,25). We therefore paid special attention were of the nodular pattern. HSs need to be differentiated (+/-) mice in the long-term experiment. All other lesions mice bearing HS in the short-term experiment and 2 female (Fig. 2B). The diffuse pattern was observed in 4 of p53 (-/-) the former, HS cells diffusely infiltrated hepatic sinusoids, forming multinucleated giant cells were sometimes present in the liver, but metastasis to other organs was relatively infrequent. In two p53 (-/-) mice, HS cells were found in multiple organs, including the spleen, lungs and blood vessels. It was possible to classify hepatic HSs into diffuse and nodular types with reference to their proliferation patterns. In the liver, but metastasis to other organs was relatively infrequent. In two p53 (-/-) mice, HS cells were found in multiple organs, including the spleen, lungs and blood vessels. It was possible to classify hepatic HSs into diffuse and nodular types with reference to their proliferation patterns. In the former, HS cells diffusely infiltrated hepatic sinusoids, forming lesions of various sizes in all liver lobes (Fig. 2A). With the latter pattern, HS cells were gathered in multicentric groups (Fig. 2B). The diffuse pattern was observed in 4 of p53 (-/-) mice bearing HS in the short-term experiment and 2 female (+/-) mice in the long-term experiment. All other lesions were of the nodular pattern. HSs need to be differentiated from lymphomas (24,25). We therefore paid special attention to the differential diagnosis as lymphoma is the most frequent spontaneous tumor in p53 knockout mice (2,13,14,17). Immunohistochemical analyses, using the murine macrophage surface marker F4/80, were used to determine tumor origin. Clusters of positively stained tumor cells were found (Fig. 2C), although F4/80 yielded various degrees of tumor cell staining within and between tumors. Additionally, HS cells did not react to either of the B- and T-lymphocyte markers, CD45R and CD3, respectively.

Pathological analysis. Macroscopically, HSs sometimes appeared as yellow-white nodules raised above the surface of the liver. However, some cases were detected by histological observation without any gross findings. In two p53 (-/-) mice with systemic invasion of HSs, markedly enlarged livers and spleens were grossly observed. Microscopically, HSs were composed of large cells with pale eosinophilic cytoplasm and pleomorphic or folded nuclei. Multinucleated giant cells were sometimes present in the neoplastic lesions (Fig. 2A) and, as previously reported, the extramedullary hematopoiesis of erythrocytic series cells was common (23). Vascular invasion of tumor cells was common in the liver, but metastasis to other organs was relatively infrequent. In two p53 (-/-) mice, HS cells were found in multiple organs, including the spleen, lungs and blood vessels. It was possible to classify hepatic HSs into diffuse and nodular types with reference to their proliferation patterns. In the former, HS cells diffusely infiltrated hepatic sinusoids, forming lesions of various sizes in all liver lobes (Fig. 2A). With the latter pattern, HS cells were gathered in multicentric groups (Fig. 2B). The diffuse pattern was observed in 4 of p53 (-/-) mice bearing HS in the short-term experiment and 2 female (+/-) mice in the long-term experiment. All other lesions were of the nodular pattern. HSs need to be differentiated from lymphomas (24,25). We therefore paid special attention to the differential diagnosis as lymphoma is the most frequent spontaneous tumor in p53 knockout mice (2,13,14,17). Immunohistochemical analyses, using the murine macrophage surface marker F4/80, were used to determine tumor origin. Clusters of positively stained tumor cells were found (Fig. 2C), although F4/80 yielded various degrees of tumor cell staining within and between tumors. Additionally, HS cells did not react to either of the B- and T-lymphocyte markers, CD45R and CD3, respectively.

Alterations of the p53 gene in HSs. The 12 HSs which developed in BHP-treated mice, 2 from p53 (+/+) and 10 from (+/-) animals, were subjected to p53 gene analysis. p53 gene mutations were identified in 8 of the 12 (66.7%) lesions. Several mutations were concurrently found in 6 of the HSs and a total of 21 mutations, concentrated in exons 5 and 8, were detected (Table III). Three (in tumors HS01, HS04 and HS10; all of them with other mutations) were silent and 2 (tumor IDs: HS04 and HS11) were of nonsense type. All the others were missense mutations. Most gave rise to transitions (19/21 = 90.5%), with G:C → T:A transitions accounting for 61.9% (13/21) of all the mutations in HSs. In HS04, a multicentric nodular lesion, 2 and 3 mutations were found in exons 5 and 8, respectively, indicating a heterogeneous cell population. To determine the alleles in which the mutations occurred, LA-PCR was performed to specifically amplify the wild-type allele of the p53 gene. Only one HS (tumor ID: HS01) from p53 (+/-) mice was successfully amplified for

**Figure 2. Histopathology of histiocytic sarcomas in p53 knockout mice. (A) Histiocytic sarcoma diffusely infiltrating in sinusoids with multinucleated**

---

Note: The figure (Figure 2) is not included in the text. It should be referenced and explained according to its content. The figure likely shows histological sections of histiocytic sarcomas in p53 knockout mice, highlighting the histological characteristics mentioned in the text.
Table III. p53 gene alterations identified in histiocytic sarcomas.

<table>
<thead>
<tr>
<th>No.</th>
<th>Tumor ID</th>
<th>Sex</th>
<th>p53 genotype</th>
<th>p53 LOH</th>
<th>p53 gene mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Exon</td>
</tr>
<tr>
<td>1</td>
<td>HS 03</td>
<td>F</td>
<td>(+/+ )</td>
<td>ND</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>HS 04</td>
<td>F</td>
<td>(+/+ )</td>
<td>ND</td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>HS 01</td>
<td>M</td>
<td>(+/-)</td>
<td>(-)</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>HS 02</td>
<td>M</td>
<td>(+/-)</td>
<td>(-)</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>HS 05</td>
<td>F</td>
<td>(+/-)</td>
<td>(-)</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>HS 06</td>
<td>F</td>
<td>(+/-)</td>
<td>(-)</td>
<td>8</td>
</tr>
<tr>
<td>7</td>
<td>HS 07</td>
<td>F</td>
<td>(+/-)</td>
<td>(-)</td>
<td>5</td>
</tr>
<tr>
<td>8</td>
<td>HS 08</td>
<td>F</td>
<td>(+/-)</td>
<td>(-)</td>
<td>5</td>
</tr>
<tr>
<td>9</td>
<td>HS 09</td>
<td>F</td>
<td>(+/-)</td>
<td>(-)</td>
<td>5</td>
</tr>
<tr>
<td>10</td>
<td>HS 10</td>
<td>F</td>
<td>(+/-)</td>
<td>(-)</td>
<td>8</td>
</tr>
<tr>
<td>11</td>
<td>HS 11</td>
<td>F</td>
<td>(+/-)</td>
<td>(-)</td>
<td>5</td>
</tr>
<tr>
<td>12</td>
<td>HS 12</td>
<td>F</td>
<td>(+/-)</td>
<td>(-)</td>
<td>5</td>
</tr>
</tbody>
</table>

exon 7, and no mutation was identified in the wild-type allele. The other microdissected samples could not be subjected to LA-PCR analysis due to poor preservation of genomic DNA in the paraffin-embedded samples. Primers for the PCR-SSCP analysis were used to amplify the wild-type allele of exon 5, and it was revealed that 5 of 7 HSs had missense mutations in exon 5 (tumor IDs: HS07, 09, 10, 11 and 12) of the p53 wild-type allele in p53 (+/-) mice. This indicated the anticipated complete loss of functional p53 protein.

Discussion

This study clearly demonstrated that p53 knockout mice are highly susceptible to BHP-induction of HS. Thus, in the short-term experiment, lesions were found in only BHP-treated p53 (-/-) mice, indicating that the complete loss of p53 dramatically accelerated the genesis of HS. The high susceptibility of p53 (-/-) mice was consistent with data for BHP-induced lung and hepatic vascular tumors (20), as well as stomach (21), esophageal (22), tongue (26), colon (27), and urinary bladder (28) carcinogenesis due to other carcinogens.

With long-term treatment of BHP, the significantly greater yield of HSs in p53 (+/-) mice as compared to p53 (+/+) mice again pointed to elevated susceptibility, especially in females. Furthermore, PCR-SSCP and sequencing analysis revealed a high frequency of p53 gene mutations, with the expected complete loss of functional protein in the BHP-induced HS. This is in agreement with earlier reports that the accelerated induction of neoplasms by chemical carcinogens in p53 (+/-) mice is accompanied by the loss of functional p53 through mutational inactivation (20,22,29,30) or the loss of heterozygosity (31). In accordance with Knudson’s two-hit hypothesis, the data point to a necessity for a ‘second hit’ to inactivate the residual normal allele.

To the best of our knowledge, this is the first report to directly demonstrate the relevance of p53 to murine HS development. The tumor suppressor p53 prevents the propagation of genetically damaged cells by the transcriptional regulation of downstream genes (1). As well, increased development of HS has been described in animals genetically engineered for genes downstream of p53, such as p21-deficient and BAX/ARF double-deficient mice (8,10). Furthermore, Carrasco et al...
demonstrated that p53 expression was frequently repressed, correlating with ARF promoter methylation in human HS (12). The fact that a deficiency of p53 accelerated the development of HSs is in line with our expectations.

BHP is a multi-organ genotoxic carcinogen which induces various types of tumors in rodents. Through oral administration, it induces lung and hepatic vascular tumors in mice (19). In addition to these tumors (20), though HS induction has not previously been reported in any rodents, including genetically engineered mice (32,33), BHP unexpectedly induced HSs in p53 knockout mice. Target organs may become altered in genetically engineered mice, reflecting organ-specific sensitivity as indicated for rasH2 mice (34). Thus, p53 knockout mice might not be expected to share the same target organs as wild-type mice because the susceptibility of p53 (+/-) mice to chemical carcinogens is organ-dependent (20,35,36). Ozaki et al reported that, when comparing susceptibilities of rasH2 and p53 (+/-) mice under the same experimental conditions, different types of tumors—lung tumors in rasH2 mice and hepatic hemangiomatas in p53 (+/-) mice—were predominantly induced by urethane treatment (37). When genetically engineered mice are used in carcinogenic studies, we must take this characteristic into consideration. Besides the deficiency of p53, the genetic background of p53 knockout mice might partly affect the development of HS. It appears that the spontaneous development of HS is more frequent in the C57BL/6d strain than in other common strains. In all cases, the development of HS is infrequent until 18 months of age, but rapidly increases in mice older than 24 months, specifically in C57BL/6d mice (4,5,7,24).

In conclusion, this study clearly shows an elevated susceptibility of nullizygous and heterozygous p53 knockout mice to BHP-induction of HS, with the direct involvement of p53. Our results support a recent study indicating HS susceptibility of the p53 knockout mouse esophagus to N-bis(2-hydroxypropyl)nitrosamine carcinogenesis. Carcinogenesis 23: 371-383, 2002.

Acknowledgements

We thank Dr Malcolm A. Moore for revision of the scientific English language. This study was supported in part by Grants-in-Aid from the Ministry of Health, Labour and Welfare and the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References


